Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NNOX.

← Back to Free Index

NNOX

Analysis as of: 2026-07-28

Nano-X Imaging Ltd.

Nanox develops lower-cost 3D imaging systems and sells related clinical software, cloud workflow, AI, and radiology service capabilities.

ai cloud healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Distressed Option on Activated Imaging Workflows

A cleared device plus service stack creates real upside, but only after financing, activation speed, and recurring utilization line up. The equity looks like a distressed option on turning low-cost imaging access into a trusted workflow business.

Analysis

Thesis

Nanox is a financing-gated option on turning a cleared low-cost imaging device into a recurring clinical workflow business; if it secures runway and activates sites fast enough, reading, AI, cloud, and health IT can compound much faster than hardware placements alone.

Last Economy Alignment

Cheaper AI helps if Nanox owns a verified imaging workflow, but capital and activation bottlenecks keep it from being a pure AI-era winner today.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

14.3x (from 5 most recent analyses)

Reasoning

The upside is not from box shipments alone. If distributor deals become live clinical sites, each active site can pull recurring reading, AI, cloud, and workflow revenue, making the business look less like a device vendor and more like a service network. Because the equity trades at distressed levels, moderate commercialization success can create outsized shareholder returns.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

This is a sequence-risk story. Nanox first needs financing, then faster install-to-activation conversion, then proof that live sites generate durable recurring revenue beyond the device. The upside is real because the starting valuation is distressed and the bundle can shift value capture toward regulated trust and workflow, but failure at any gate can trigger dilution before the flywheel forms.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On July 24, 2026, the prospectus supplement made the financing bottleneck more explicit by showing about $53.9 million remained on the ATM but full use would require more authorized shares.
By July 28, 2026, the share price had fallen to roughly $0.88, pushing market value near $51 million and increasing expected dilution per dollar raised.
There was no fresh deployment or utilization disclosure in the last 7-10 days, so the near-term story shifted further from commercialization promise toward financing mechanics.

Forecast update

A lower starting equity value now creates more upside if commercialization works, while the latest financing disclosures also make the path more fragile.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.31

They control a regulated imaging device and can attach reading, cloud, and AI services to each live site, which is where AI-era value could compound. The problem is simple: cash, permits, and slow activations can stop that flywheel before it becomes hard to copy.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$5.13

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research